Srilatha Edupuganti

Emory University - School of Medicine

1364 Clifton Rd. NE

Atlanta, GA 30322

United States

SCHOLARLY PAPERS

6

DOWNLOADS

263

TOTAL CITATIONS

3

Scholarly Papers (6)

1.

Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against SARS-CoV-2 Omicron Variant

Number of pages: 57 Posted: 08 Apr 2022
University of Maryland - Center for Vaccine Development and Global Health, Baylor College of Medicine, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, affiliation not provided to SSRN, affiliation not provided to SSRN, University of Maryland - School of Medicine, Duke University - Duke Human Vaccine Institute, Kaiser Permanente Washington Health Research Institute, University of Rochester - Division of Infectious Diseases, Baylor College of Medicine, Emory University School of Medicine and Children’s Healthcare of Atlanta - Department of Pediatrics, University of Pittsburgh - School of Medicine, University of Washington, University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences, New York University (NYU) - Grossman School of Medicine, University of Cincinnati - College of Medicine, Cincinnati Children's Hospital Medical Center - Division of Infectious Diseases, New York University (NYU) - New York University Long Island School of Medicine, New York University (NYU) - Grossman School of Medicine, affiliation not provided to SSRN, University of Pittsburgh - School of Medicine, Emory University - School of Medicine, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), affiliation not provided to SSRN, University of Washington - Vaccine and Infectious Disease Division, University of Maryland - Center for Vaccine Development and Global Health, affiliation not provided to SSRN, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Emory University - Center for Childhood Infections and Vaccines, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Duke University - Duke Human Vaccine Institute and affiliation not provided to SSRN
Downloads 68 (683,426)
Citation 3

Abstract:

Loading...

COVID-19, SARS-CoV-2, Booster, Vaccine, Omicron variant, B.1.1.529, Neutralizing antibody, mRNA vaccine, recombinant adenovirus vaccine

2.

Pharmacokinetic Serum Concentrations of VRC01 Correlate with Prevention of HIV-1 Acquisition

Number of pages: 35 Posted: 18 Oct 2022
Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University, Duke University - School of Medicine, Duke University - School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Independent, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Washington, University of Cape Town (UCT) - Institute of Infectious Disease and Molecular Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of Washington - Department of Biostatistics, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Family Health International, Via Libre CRS, University of California, Los Angeles (UCLA) - Department of Medicine, Wits Health Consortium - Perinatal HIV Research Unit (PHRU), University of Cape Town (UCT) - Department of Medicine, University of Pennsylvania, Asociacion Civil Impacta Salud y Educacion, Emory University - School of Medicine, San Miguel Clinical Research Center - Asociacion Civil Impacta Salud y Educacion, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, National Institute for Communicable Diseases of the National Health Laboratory Service, Duke University - Duke Human Vaccine Institute, University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division and Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology
Downloads 56 (751,045)

Abstract:

Loading...

body weight, HIV, prevention, broadly neutralizing antibodies, monoclonal antibody, pharmacokinetics

3.

Baseline Host Determinants of Robust Human HIV-1 Vaccine- Induced Immune Responses: A Meta-Analysis of 26 Vaccine Regimens

Number of pages: 43 Posted: 11 Apr 2022
Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of KwaZulu-Natal - Centre for the AIDS Programme of Research in South Africa, University of Manitoba, Instituto Nacional de Saude, South African Medical Research Council, Aurum Institute, University of California, San Francisco (UCSF) - Department of Epidemiology and Biostatistics, Emory University - School of Medicine, University of Cape Town (UCT) - Desmond Tutu HIV Foundation, University of Rochester - School of Medicine and Dentistry, University of North Carolina (UNC) at Chapel Hill - UNC-Project Malawi, University of Alabama at Birmingham - Heersink School of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, University of Rochester - School of Medicine and Dentistry, University of Alabama at Birmingham, Fenway Community Health - The Fenway Institute, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, affiliation not provided to SSRN, Independent and affiliation not provided to SSRN
Downloads 53 (770,257)

Abstract:

Loading...

Baseline characteristics, SuperLearner, Variable importance measurements, Vaccine response heterogeneity, Antibody, CD4+ T cell

4.

Infusion Reactions in Persons Receiving the Broadly Neutralizing Antibody VRC01 or Placebo for Reduction of HIV-1 Acquisition: Results From the Phase 2b Antibody Mediated Prevention (AMP) Randomized Trials

Number of pages: 30 Posted: 14 May 2021
Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Emory University - School of Medicine, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center, National Institutes of Health - Vaccine Research Center, Botswana Harvard AIDS Institute Partnership (BHP), University of Cape Town (UCT) - Institute of Infectious Disease and Molecular Medicine, South African Medical Research Council, Asociacion Civil Impacta Salud y Educacion, Oswaldo Cruz Foundation (FIOCRUZ) - Instituto Nacional de Infectologia Evandro Chagas (INIEC), Harvard University - Brigham and Women’s Hospital, Family Health International, Fred Hutchinson Cancer Research Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Government of the United States of America - National Institutes of Health (NIH), Government of the United States of America - National Institutes of Health (NIH), Government of the United States of America - National Institutes of Health (NIH), Government of the United States of America - National Institutes of Health (NIH), University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center, Aurum Institute and University of Zimbabwe - Clinical Trials Research Centre
Downloads 37 (909,275)

Abstract:

Loading...

infusion related reactions, hypersensitivity, broadly neutralizing antibodies, AMP study, HIV

5.

Fixed Dosing Versus Weight-Based Dosing of HIV-1 Prophylactic Monoclonal Antibodies in Adults: A Pharmacokinetics Modeling Study

Number of pages: 23 Posted: 14 Jan 2025
Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Family Health International, HPTN Leadership and Operations Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Government of the United States of America - National Institute of Allergy and Infectious Diseases, Fred Hutchinson Cancer Research Center, Harvard University - Brigham and Women’s Hospital, University of North Carolina (UNC) at Chapel Hill - School of Medicine, Government of the United States of America - National Institute of Allergy and Infectious Diseases, Kelly Government Solutions, Columbia University - Aaron Diamond AIDS Research Center, Columbia University - Irving Medical Center, Emory University - School of Medicine, University of North Carolina (UNC) at Chapel Hill, Harvard University - Beth Israel Deaconess Medical Center, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Emory University - Division of Infectious Diseases, University of KwaZulu-Natal - Centre for the AIDS Programme of Research in South Africa (CAPRISA), George Washington University - School of Medicine and Health Sciences, National Institutes of Health, Government of the United States of America - National Institute of Allergy and Infectious Diseases, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, University of North Carolina (UNC) at Chapel Hill - Department of Medicine, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center - Vaccine and Infectious Disease Division, National Institutes of Health - Vaccine Research Center and Duke University - Departments of Surgery, Immunology, Molecular Genetics and Microbiology
Downloads 35 (909,275)

Abstract:

Loading...

HIV prevention, dosing strategy, exponent of body weight, two-compartment, population pharmacokinetics model, variability in exposure

6.

Pre-Existing Memory B Cell Phenotypes Determine the Quality of B Cell Response to Vaccine Boosters

Number of pages: 31 Posted: 24 Dec 2024
Government of the United States of America - Vaccine Research Center, Government of the United States of America - National Institute of Allergy and Infectious Diseases, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, National Institutes of Health - Vaccine Research Center, University of Maryland - Center for Vaccine Development and Global Health, Baylor College of Medicine, University of Maryland - School of Medicine, Kaiser Permanente Washington Health Research Institute, University of Rochester - Division of Infectious Diseases, Emory University School of Medicine and Children’s Healthcare of Atlanta - Department of Pediatrics, University of Pittsburgh - School of Medicine, University of Washington, University of Texas Medical Branch-Galveston - The Sealy Institute for Vaccine Sciences, New York University (NYU) - Grossman School of Medicine, University of Cincinnati - College of Medicine, New York University (NYU) - New York University Long Island School of Medicine, Emory University - School of Medicine, Independent, Fred Hutchinson Cancer Research Center, Government of the United States of America - National Institute of Allergy and Infectious Diseases (NIAID), Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Government of the United States of America - Vaccine Research Center, Independent and Government of the United States of America - Vaccine Research Center
Downloads 14 (1,141,526)

Abstract:

Loading...

SARS-CoV-2 vaccine, prime-boost, B cell phenotype, atypical B cells, single-cell sequencing